Published in Clin Cancer Res on August 01, 2008
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst (2010) 4.80
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One (2010) 3.96
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet (2012) 3.20
Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer (2010) 2.41
Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst (2011) 1.92
MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis (2012) 1.40
Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis. J Thorac Oncol (2011) 1.32
A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med (2011) 1.14
Quantitative proteomics reveals regulation of karyopherin subunit alpha-2 (KPNA2) and its potential novel cargo proteins in nonsmall cell lung cancer. Mol Cell Proteomics (2012) 1.14
Update in lung cancer 2008. Am J Respir Crit Care Med (2009) 1.11
Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis (2010) 1.11
Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front Physiol (2014) 1.11
Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res (2011) 1.00
The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis (2010) 0.93
Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens. BMC Cancer (2011) 0.92
A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology. PLoS One (2010) 0.91
A signature inferred from Drosophila mitotic genes predicts survival of breast cancer patients. PLoS One (2011) 0.83
Gene expression from bronchoscopy obtained tumour samples as a predictor of outcome in advanced inoperable lung cancer. PLoS One (2012) 0.82
Lung cancer therapeutics that target signaling pathways: an update. Expert Rev Respir Med (2010) 0.82
Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for lung cancer: A marker phase I trial. Thorac Cancer (2014) 0.82
Cancer module genes ranking using kernelized score functions. BMC Bioinformatics (2012) 0.82
ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer. BMC Cancer (2016) 0.79
Vav1 promotes lung cancer growth by instigating tumor-microenvironment cross-talk via growth factor secretion. Oncotarget (2014) 0.78
Three-gene signature predicts disease progression of non-muscle invasive bladder cancer. Oncol Lett (2011) 0.78
Using logistic regression to improve the prognostic value of microarray gene expression data sets: application to early-stage squamous cell carcinoma of the lung and triple negative breast carcinoma. BMC Med Genomics (2014) 0.78
Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol (2014) 0.76
Clinical significance and prognostic value of Vav1 expression in Non-small cell lung cancer. Am J Cancer Res (2015) 0.76
Yin Yang gene expression ratio signature for lung cancer prognosis. PLoS One (2013) 0.76
Lung Cancer Gene Signatures and Clinical Perspectives. Microarrays (Basel) (2013) 0.75
Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics (2015) 0.75
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 13.47
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 10.41
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol (2008) 4.24
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol (2007) 4.23
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst (2007) 4.07
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2012) 3.89
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol (2007) 3.88
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst (2002) 3.54
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2012) 3.43
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature (2011) 3.18
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res (2011) 3.15
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res (2002) 2.96
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res (2005) 2.81
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.59
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res (2004) 2.54
Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst (2008) 2.45
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst (2004) 2.41
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer (2006) 2.40
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol (2007) 2.35
Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun (2002) 2.09
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res (2004) 2.09
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet (2004) 2.05
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res (2009) 2.03
Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol (2013) 1.91
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene (2003) 1.88
BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One (2007) 1.86
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer (2004) 1.82
Bronchioloalveolar carcinoma: a review. Clin Lung Cancer (2006) 1.81
Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol (2010) 1.79
Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. Int J Cancer (2010) 1.76
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol (2008) 1.76
Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J Clin Invest (2007) 1.73
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer (2005) 1.71
Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys (2008) 1.68
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol (2007) 1.66
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med (2009) 1.62
Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett (2003) 1.60
Circulating MicroRNA Signatures of Tumor-Derived Exosomes for Early Diagnosis of Non-Small-Cell Lung Cancer. Clin Lung Cancer (2009) 1.60
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res (2014) 1.59
Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer (2005) 1.57
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood (2006) 1.57
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55